ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Tacrolimus Levels in Patients Treated with Direct Acting Antivirals Post-Transplant.

J. Wiegel, T. Egbuka.

Pharmacy, Oregon Health & Science University, Portland, OR.

Meeting: 2016 American Transplant Congress

Abstract number: D291

Keywords: FK506, Hepatitis C, Immunosuppression, Liver transplantation

Session Information

Date: Tuesday, June 14, 2016

Session Name: Poster Session D: Viral Hepatitis

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Halls C&D

Related Abstracts
  • Treatment of Hepatitis C Viral Infection with Novel Direct Acting Antivirals in Kidney Transplant Recipients – Single Center Experience.
  • Direct-Acting Antivirals for Hepatitis C Treatment in Kidney Transplant Recipients.

Purpose: To determine if treatment of recurrent hepatitis C virus (HCV) post-liver transplant with the direct-acting antivirals (DAAs) sofosbuvir, simeprevir, and ledipasvir (in combination and/or with or without ribavirin and/or peginterferon alfa) is associated with a significant decrease in tacrolimus levels.

Methods: We performed a retrospective chart review of all post-liver transplant patients with recurrent HCV who were treated with DAAs at our institution from January 2014 to present. Patients were excluded if they had started HCV treatment but had not yet finished and if they were receiving an immunosuppression regimen that did not include tacrolimus. Eligible patients were identified through the electronic health record. Individual chart review was conducted to collect patient demographics, transplant data, labs, and HCV infection data. Data were collected using Microsoft Excel and analyzed using IBM SPSS software.

Results: A total of 60 patients were included in the analysis.

Demographics (N=60)  
Age 59 (18-73)
Female 30%
Genotype 1 90%
Cirrhosis 20%
Mean HCV RNA 8.3 million copies/mL

Mean tacrolimus levels at baseline were 7.2 mcg/L.

  Mean Tacrolimus Levels (mcg/mL) Difference in Mean Level From Baseline
Baseline 7.2 N/A
Treatment Week 4 5.9 -1.3 (p=0.007)
Treatment Week 12 4.6 -2.6 (p<0.001)
12 Weeks Post-Treatment 4.2 -3 (p<0.001)

By week 4 of HCV treatment, mean tacrolimus levels were significantly lower than baseline at 5.9 mcg/L (p=0.007). Mean tacrolimus levels remained significantly lower than baseline at treatment week 12 and at 12 weeks after the completion of treatment with mean levels of 4.6 mcg/L (p<0.001) and 4.2 mcg/L (p<0.001), respectively. There were no statistically significant differences in tacrolimus levels between the different HCV treatment groups at any time point during HCV treatment. There were no episodes of biopsy-proven rejection for any patients while on HCV treatment.

Conclusion: Although there are no drug interactions reported between tacrolimus and the DAAs sofosbuvir, simeprevir, or ledipasvir, our study demonstrated significant decreases in tacrolimus levels starting as early as week 4 of HCV treatment and which continued throughout the duration of HCV treatment and at 12 weeks following the completion of HCV treatment.

CITATION INFORMATION: Wiegel J, Egbuka T. Tacrolimus Levels in Patients Treated with Direct Acting Antivirals Post-Transplant. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Wiegel J, Egbuka T. Tacrolimus Levels in Patients Treated with Direct Acting Antivirals Post-Transplant. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/tacrolimus-levels-in-patients-treated-with-direct-acting-antivirals-post-transplant/. Accessed February 24, 2021.

« Back to 2016 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
      • Weight Loss, But Not Weight Gain Is a Risk Factor for Graft Loss After Kidney Transplantation

      Visit Our Partner Sites

      American Transplant Congress (ATC)

      Visit the official site for the American Transplant Congress »

      American Journal of Transplantation

      The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

      American Society of Transplantation (AST)

      An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

      American Society of Transplant Surgeons (ASTS)

      The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

      Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

      Privacy Policy

      loading Cancel
      Post was not sent - check your email addresses!
      Email check failed, please try again
      Sorry, your blog cannot share posts by email.
      This site uses cookies: Find out more.